Call 08047308287 76% Response Rate

Send Email

Anti Cancer Tablet And Injection

Our range of products include sandostatin lar octreotide 20mg/30mg injection and piclib palbociclib 125mg tablet.
Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection

Sandostatin LAR Octreotide 20mg/30mg Injection

Get Latest Price

Product Brochure

Product Details:
Dose / Strength30 mcg/ml
Packaging TypeVial
CompositionOctreotide Long Acting Release Injection
BrandSandostatin LAr 20/30 MG
Prescription/Non prescriptionPrescription
ManufacturerNovartis
Usage/ApplicationHospital
Sandostatin LAR Depot (octreotide acetate) is an octapeptide used to treat acromegaly. Sandostatin LAR Depot is also used to reduce flushing episodes and watery diarrhea caused by cancerous tumors (carcinoid syndrome) or tumors called vasoactive intestinal peptide tumors (VIP adenomas).
Get Best QuoteRequest A Callback
Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet

Piclib Palbociclib 125mg Tablet

Get Latest Price

Product Brochure

Product Details:
Packaging Size1*21 Tablets
BrandPiclib 125mg Tablet
CompositionPalbociclib
Prescription/Non prescriptionPrescription
FormTablet
TreatmentHR+,HER2- Locally advanced or Metastatic Breast Cancer
Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.2). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist. 
Get Best QuoteRequest A Callback

EXPLORE MORE CATEGORIES

Contact Us
 
Thank youYour Enquiry has been sent successfully.
© Speciality Healthcare Solutions. All Rights Reserved (Terms of Use)Developed and managed by IndiaMART InterMESH Ltd.